---
title: "Moderna, Inc. (MRNA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MRNA.US.md"
symbol: "MRNA.US"
name: "Moderna, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T21:27:53.709Z"
locales:
  - [en](https://longbridge.com/en/quote/MRNA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MRNA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MRNA.US.md)
---

# Moderna, Inc. (MRNA.US)

## Company Overview

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.modernatx.com](https://www.modernatx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.72)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 202 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -29.97% |  |
| Net Profit YoY | 4.86% |  |
| P/B Ratio | 2.58 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 19079793930.82 |  |
| Revenue | 2225000000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -36.56% | E |
| Profit Margin | -143.55% | E |
| Gross Margin | -86.63% | E |
| Revenue YoY | -29.97% | E |
| Net Profit YoY | 4.86% | C |
| Total Assets YoY | -9.57% | E |
| Net Assets YoY | -26.41% | E |
| Cash Flow Margin | 45.90% | C |
| OCF YoY | -29.97% | E |
| Turnover | 0.18 | D |
| Gearing Ratio | 35.52% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Moderna, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-29.97%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "4.86%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.58",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "19079793930.82",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2225000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-36.56%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-143.55%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-86.63%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-29.97%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "4.86%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-9.57%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-26.41%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "45.90%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-29.97%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.18",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "35.52%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.97 | 395/386 | - | - | - |
| PB | 2.58 | 225/386 | 2.24 | 1.19 | 1.04 |
| PS (TTM) | 8.58 | 154/386 | 9.37 | 4.29 | 3.29 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **23**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 9% |
| Overweight | 2 | 9% |
| Hold | 16 | 70% |
| Underweight | 2 | 9% |
| Sell | 1 | 4% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 45.72 |
| Highest Target | 69.00 |
| Lowest Target | 21.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MRNA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MRNA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MRNA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MRNA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**